Immunoregulatory nanomedicine for respiratory infections
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Respiratory viral infections research · Immunotherapy and Immune Responses · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Dowell, S. F. & Ho, M. S. Seasonality of infectious diseases and severe acute respiratory syndrome—what we don’t know can hurt us. Lancet Infect. Dis. 4, 704–708 (2004).10.1016/S1473-3099(04)01177-6 ↗
2. Bygbjerg, I. C. Double burden of noncommunicable and infectious diseases in developing countries. Science 337, 1499–1501 (2012).10.1126/science.1223466 ↗
3. Baker, R. E. et al. Infectious disease in an era of global change. Nat. Rev. Microbiol. 20, 193–205 (2022).10.1038/s41579-021-00639-z ↗
4. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).10.1016/S1473-3099(20)30120-1 ↗
5. Mosier, D. A. Bacterial pneumonia. Vet. Clin. North. Am. Food Anim. Pract. 13, 483–493 (1997).10.1016/S0749-0720(15)30310-8 ↗
6. Bradley, B. T. & Bryan, A. Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella. Semin. Diagn. Pathol. 36, 152–159 (2019).10.1053/j.semdp.2019.04.006 ↗
7. Shao, X. et al. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175, 3244–3251 (2005).10.4049/jimmunol.175.5.3244 ↗
8. Zhou, P. & Shi, Z.-L. SARS-CoV-2 spillover events. Science 371, 120–122 (2021).10.1126/science.abf6097 ↗
9. Abraham, E. et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit. Care Med. 28, 232–235 (2000).10.1097/00003246-200001000-00039 ↗
10. DiSilvio, B. et al. Complications and outcomes of acute respiratory distress syndrome. Crit. Care Med. 42, 349–361 (2019).
11. Li, K. et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J. Infect. Dis. 213, 712–722 (2016).10.1093/infdis/jiv499 ↗
12. Singh, A. Eliciting B cell immunity against infectious diseases using nanovaccines. Nat. Nanotechnol. 16, 16–24 (2021).10.1038/s41565-020-00790-3 ↗
13. Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553–559 (2021).10.1038/s41586-021-03594-0 ↗
14. Su, Z. et al. Bioresponsive nano-antibacterials for H2S-sensitized hyperthermia and immunomodulation against refractory implant-related infections. Sci. Adv. 8, eabn1701 (2022).10.1126/sciadv.abn1701 ↗
15. Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug. Discov. 20, 817–838 (2021).10.1038/s41573-021-00283-5 ↗
16. Wareing, M. D. & Tannock, G. A. Live attenuated vaccines against influenza; an historical review. Vaccine 19, 3320–3330 (2001).10.1016/S0264-410X(01)00045-7 ↗
17. Skountzou, I. et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28, 4103–4112 (2010).10.1016/j.vaccine.2009.07.058 ↗
18. Ellebedy, A. H. et al. Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) virus vaccination in ferrets. Clin. Vaccine Immunol. 17, 1998–2006 (2010).10.1128/CVI.00247-10 ↗
19. Ninomiya, A. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 20, 3123–3129 (2002).10.1016/S0264-410X(02)00261-X ↗
20. Roy, S. et al. Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes. Vaccine 37, 1266–1276 (2019).10.1016/j.vaccine.2019.01.045 ↗
21. Mielcarek, N., Alonso, S. & Locht, C. Nasal vaccination using live bacterial vectors. Adv. Drug. Deliv. Rev. 51, 55–69 (2001).10.1016/S0169-409X(01)00168-5 ↗
22. Wu, Y. et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci. Transl. Med. 13, eabg1143 (2021).10.1126/scitranslmed.abg1143 ↗
23. Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).10.1038/s41467-020-16505-0 ↗
24. Narasimhan, M. et al. Serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines. Vaccines 9, 708 (2021).10.3390/vaccines9070708 ↗
25. Berkhout, B., Verhoef, K., van Wamel, J. L. B. & Back, N. K. T. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J. Virol. 73, 1138–1145 (1999).10.1128/JVI.73.2.1138-1145.1999 ↗
26. Cevik, M. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell 184, 5077–5081 (2021).10.1016/j.cell.2021.09.010 ↗
27. Khalaj‐Hedayati, A., Chua, C. L. L., Smooker, P. & Lee, K. W. Nanoparticles in influenza subunit vaccine development: immunogenicity enhancement. Influenza Other Resp. Vir. 14, 92–101 (2020).10.1111/irv.12697 ↗
28. Kim, C. G., Kye, Y.-C. & Yun, C.-H. The role of nanovaccine in cross-presentation of antigen-presenting cells for the activation of CD8+ T cell responses. Pharmaceutics 11, 612 (2019).10.3390/pharmaceutics11110612 ↗
29. Silva, A. L., Soema, P. C., Slütter, B., Ossendorp, F. & Jiskoot, W. PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Hum. Vaccines Immunother. 12, 1056–1069 (2016).10.1080/21645515.2015.1117714 ↗
30. Huang, J. et al. Nasal nanovaccines for SARS-CoV-2 to address COVID-19. Vaccines 10, 405 (2022).10.3390/vaccines10030405 ↗
31. Hussain, A. et al. mRNA vaccines for COVID-19 and diverse diseases. J. Control. Rel. 345, 314–333 (2022).10.1016/j.jconrel.2022.03.032 ↗
32. Meng, Q. et al. Capturing cytokines with advanced materials: a potential strategy to tackle COVID‐19 cytokine storm. Adv. Mater. 33, 2100012 (2021).10.1002/adma.202100012 ↗
33. Hotchkiss, R. S., Coopersmith, C. M., McDunn, J. E. & Ferguson, T. A. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15, 496–497 (2009).10.1038/nm0509-496 ↗
34. van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 39–50 (2022).10.1038/s41591-021-01643-9 ↗
35. Wykes, M. N. & Lewin, S. R. Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol. 18, 91–104 (2018).10.1038/nri.2017.112 ↗
36. Florindo, H. F. et al. Immune-mediated approaches against COVID-19. Nat. Nanotechnol. 15, 630–645 (2020).10.1038/s41565-020-0732-3 ↗
37. Jiang, S., Zhang, X., Yang, Y., Hotez, P. J. & Du, L. Neutralizing antibodies for the treatment of COVID-19. Nat. Biomed. Eng. 4, 1134–1139 (2020).10.1038/s41551-020-00660-2 ↗
38. Nasiruddin, M., Neyaz, Md. K. & Das, S. Nanotechnology-based approach in tuberculosis treatment. Tuberc. Res. Treat. 2017, 1–12 (2017).
39. Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637–1645 (2021).10.1016/S0140-6736(21)00676-0 ↗
40. The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491–1502 (2021).10.1056/NEJMoa2100433 ↗
41. Kozlov, M. Omicron overpowers key COVID antibody treatments in early tests. Nature https://doi.org/10.1038/d41586-021-03829-0 (2021).10.1038/d41586-021-03829-0 ↗
42. Roback, J. D. & Guarner, J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 323, 1561–1562 (2020).10.1001/jama.2020.4940 ↗
43. Nguyen, P. T. N., Nho Van Le, Nguyen Dinh, H. M., Nguyen, B. Q. P. & Nguyen, T. V. A. Lung penetration and pneumococcal target binding of antibiotics in lower respiratory tract infection. Curr. Med. Res. Opin. 38, 2085–2095 (2022).10.1080/03007995.2022.2131304 ↗
44. Qiao, Q. et al. Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design. Acta Pharm. Sin. B 11, 3060–3091 (2021).10.1016/j.apsb.2021.04.023 ↗
45. Duan, Y., Wang, S., Zhang, Q., Gao, W. & Zhang, L. Nanoparticle approaches against SARS-CoV-2 infection. Curr. Opin. Solid. State Mater. Sci. 25, 100964 (2021).10.1016/j.cossms.2021.100964 ↗
46. Doroudian, M., MacLoughlin, R., Poynton, F., Prina-Mello, A. & Donnelly, S. C. Nanotechnology based therapeutics for lung disease. Thorax 74, 965–976 (2019).10.1136/thoraxjnl-2019-213037 ↗
47. Yang, H. et al. Amino acid-dependent attenuation of Toll-like receptor signalling by peptide-gold nanoparticle hybrids. ACS Nano 9, 6774–6784 (2015).10.1021/nn505634h ↗
48. Gao, Y., Dai, W., Ouyang, Z., Shen, M. & Shi, X. Dendrimer-mediated intracellular delivery of fibronectin guides macrophage polarization to alleviate acute lung injury. Biomacromolecules 24, 886–895 (2023).10.1021/acs.biomac.2c01318 ↗
49. Liu, F.-C. et al. Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. J. Nanobiotechnol. 16, 35 (2018).10.1186/s12951-018-0364-z ↗
50. Kou, M. et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis. 13, 580 (2022).10.1038/s41419-022-05034-x ↗
51. Liu, W. et al. Recent advances of cell membrane-coated nanomaterials for biomedical applications. Adv. Funct. Mater. 30, 2003559 (2020).10.1002/adfm.202003559 ↗
52. Brahmakshatriya, V. et al. IL-6 production by TLR-activated APC broadly enhances aged cognate CD4 helper and B cell antibody responses in vivo. J. Immunol. 198, 2819–2833 (2017).10.4049/jimmunol.1601119 ↗
53. Hong, S. et al. B cells are the dominant antigen-presenting cells that activate naive CD4+ T cells upon immunization with a virus-derived nanoparticle antigen. Immunity 49, 695–708 (2018).10.1016/j.immuni.2018.08.012 ↗
54. Denzel, A. et al. Basophils enhance immunological memory responses. Nat. Immunol. 9, 733–742 (2008).10.1038/ni.1621 ↗
55. Kim, J. et al. Self-assembled mRNA vaccines. Adv. Drug. Deliv. Rev. 170, 83–112 (2021).10.1016/j.addr.2020.12.014 ↗
56. Nakahashi-Ouchida, R., Fujihashi, K., Kurashima, Y., Yuki, Y. & Kiyono, H. Nasal vaccines: solutions for respiratory infectious diseases. Trends Mol. Med. 29, 124–140 (2023).10.1016/j.molmed.2022.10.009 ↗
57. Soema, P. C., Kompier, R., Amorij, J.-P. & Kersten, G. F. A. Current and next generation influenza vaccines: formulation and production strategies. Eur. J. Pharm. Biopharm. 94, 251–263 (2015).10.1016/j.ejpb.2015.05.023 ↗
58. Nemes, E. et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N. Engl. J. Med. 379, 138–149 (2018).10.1056/NEJMoa1714021 ↗
59. Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S. & Archambault, D. Nanoparticle-based vaccines against respiratory viruses. Front. Immunol. 10, 22 (2019).10.3389/fimmu.2019.00022 ↗
60. Li, M. et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal. Transduct. Target. Ther. 7, 146 (2022).10.1038/s41392-022-00996-y ↗
61. Tiboni, M., Casettari, L. & Illum, L. Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines? Int. J. Pharm. 603, 120686 (2021).10.1016/j.ijpharm.2021.120686 ↗
62. Weng, Y. et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv. 40, 107534 (2020).10.1016/j.biotechadv.2020.107534 ↗
63. Guo, S. et al. Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment. Exploration 1, 35–49 (2021).10.1002/EXP.20210008 ↗
64. Yang, T. et al. Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle. Bioact. Mater. 5, 1053–1061 (2020).
65. Zhang, H. et al. Aerosolizable lipid nanoparticles for pulmonary delivery of mRNA through design of experiments. Pharmaceutics 12, 1042 (2020).10.3390/pharmaceutics12111042 ↗
66. Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059–1068 (2021).10.1038/s41551-021-00786-x ↗
67. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).10.1038/s41565-020-0669-6 ↗
68. Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).10.1073/pnas.2109256118 ↗
69. Dong, Y. et al. Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo. Nano Lett. 16, 842–848 (2016).10.1021/acs.nanolett.5b02428 ↗
70. Kaczmarek, J. C. et al. Polymer–lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew. Chem. Int. Edn 55, 13808–13812 (2016).10.1002/anie.201608450 ↗
71. Kaczmarek, J. C. et al. Optimization of a degradable polymer–lipid nanoparticle for potent systemic delivery of mRNA to the lung endothelium and immune cells. Nano Lett. 18, 6449–6454 (2018).10.1021/acs.nanolett.8b02917 ↗
72. Capasso Palmiero, U. et al. Poly(beta-amino ester)-co-poly(caprolactone) terpolymers as nonviral vectors for mRNA delivery in vitro and in vivo. Adv. Healthc. Mater. 7, 1800249 (2018).10.1002/adhm.201800249 ↗
73. Patel, A. K. et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv. Mater. 31, 1805116 (2019).10.1002/adma.201805116 ↗
74. Kaczmarek, J. C. et al. Systemic delivery of mRNA and DNA to the lung using polymer-lipid nanoparticles. Biomaterials 275, 120966 (2021).10.1016/j.biomaterials.2021.120966 ↗
75. Higuchi, A. et al. Material design for next-generation mRNA vaccines using lipid nanoparticles. Polym. Rev. 63, 394–436 (2023).10.1080/15583724.2022.2106490 ↗
76. Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat. Med. 28, 1063–1071 (2022).10.1038/s41591-022-01753-y ↗
77. Andrews, N. et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022).10.1056/NEJMoa2119451 ↗
78. Wang, K. et al. Transmission characteristics and inactivated vaccine effectiveness against transmission of SARS-CoV-2 omicron BA.5 variants in Urumqi, China. JAMA Netw. Open. 6, e235755 (2023).10.1001/jamanetworkopen.2023.5755 ↗
79. Low, J. G. et al. A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. npj Vaccines 7, 161 (2022).10.1038/s41541-022-00590-x ↗
80. Annual R&D day. Moderna https://investors.modernatx.com/events-and-presentations/events/event-details/2022/Annual-RD-Day-2022/default.aspx (2022).
81. Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327 (2017).10.1016/j.ymthe.2017.03.035 ↗
82. Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899–904 (2022).10.1126/science.abm0271 ↗
83. Miao, L., Zhang, Y. & Huang, L. mRNA vaccine for cancer immunotherapy. Mol. Cancer 20, 41 (2021).10.1186/s12943-021-01335-5 ↗
84. Shim, B. S. et al. Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. BMC Immunol. 11, 65 (2010).10.1186/1471-2172-11-65 ↗
85. Stemirna Therapeutics. Vaccine agent for treating or preventing coronavirus disease. WO2021159985A1 (World Intellectual Property Organization, 2021).
86. Yang, R. et al. A core–shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal. Transduct. Target. Ther. 6, 213 (2021).10.1038/s41392-021-00634-z ↗
87. Yan, Y. et al. Systemic mRNA delivery to the lungs by functional polyester-based carriers. Biomacromolecules 18, 4307–4315 (2017).10.1021/acs.biomac.7b01356 ↗
88. Suberi, A. et al. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Sci. Transl. Med. 15, eabq0603 (2023).10.1126/scitranslmed.abq0603 ↗
89. McKinlay, C. J. et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc. Natl. Acad. Sci. USA 114, 448–456 (2017).10.1073/pnas.1614193114 ↗
90. Haabeth, O. A. W. et al. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc. Natl. Acad. Sci. USA 115, E9153–E9161 (2018).10.1073/pnas.1810002115 ↗
91. Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210–1216 (2012).10.1038/nbt.2436 ↗
92. Qiu, Y. et al. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J. Control. Rel. 314, 102–115 (2019).10.1016/j.jconrel.2019.10.026 ↗
93. Lou, B. et al. Preparation of mRNA polyplexes with post-conjugated endosome-disruptive peptides. Methods Mol. Biol. 2355, 275–286 (2021).10.1007/978-1-0716-1617-8_21 ↗
94. Yeom, J. H. et al. Inhibition of xenograft tumor growth by gold nanoparticle-DNA oligonucleotide conjugates-assisted delivery of BAX mRNA. PLoS One 8, 75369 (2013).10.1371/journal.pone.0075369 ↗
95. Sun, P. et al. Transcellular delivery of messenger RNA payloads by a cationic supramolecular MOF platform. Chem. Commun. 54, 11304–11307 (2018).10.1039/C8CC07047D ↗
96. Tsai, S. J. et al. Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity. J. Biol. Chem. 297, 101266 (2021).10.1016/j.jbc.2021.101266 ↗
97. Zhitnyuk, Y. et al. Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochem. Biophys. Res. Commun. 505, 1097–1102 (2018).10.1016/j.bbrc.2018.09.113 ↗
98. Tacchi, L. et al. Nasal immunity is an ancient arm of the mucosal immune system of vertebrates. Nat. Commun. 5, 5205 (2014).10.1038/ncomms6205 ↗
99. Strugnell, R. A. & Wijburg, O. L. The role of secretory antibodies in infection immunity. Nat. Rev. Microbiol. 8, 656–667 (2010).10.1038/nrmicro2384 ↗
100. Jansen, E. M. et al. Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. Expert. Opin. Drug. Deliv. 19, 1471–1485 (2022).10.1080/17425247.2022.2131767 ↗